Related Experiment Videos
Pediatric uses of recombinant human erythropoietin: the outlook in 1991
1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75235.
Insights
Recombinant human erythropoietin (rHuEPO) shows promise for treating anemia in children with chronic kidney disease, but more controlled studies are needed to confirm safety and efficacy. Current data suggest favorable outcomes, but potential risks require further investigation.
Area of Science:
- Pediatric Nephrology
- Hematology
- Pharmacology
Background:
- Recombinant human erythropoietin (rHuEPO) is effective for anemia in adult dialysis patients.
- Limited published studies exist on rHuEPO use in pediatric renal anemia.
- Existing pediatric data, mostly from abstracts, suggest favorable outcomes.
Purpose of the Study:
- To review the current evidence on the safety and efficacy of rHuEPO in pediatric patients with renal anemia.
- To identify knowledge gaps and potential risks associated with rHuEPO therapy in children.
- To provide preliminary recommendations for rHuEPO use in pediatric populations.
Main Methods:
- Review of published literature and abstracts on rHuEPO therapy in pediatric patients.
- Analysis of reported efficacy in resolving renal anemia and transfusion dependency.
- Assessment of reported adverse events, including hypertension, seizures, and thrombosis.
Main Results:
- Over 257 pediatric patients have been reported, with high rates of anemia resolution and decreased transfusion dependency.
- Hypertension is a notable adverse event, occurring in up to one-third of treated children.
- Risks of seizures, thrombosis, hyperkalemia, hyperphosphatemia, and peritonitis remain unclear due to lack of controlled trials.
Conclusions:
- rHuEPO therapy holds significant potential to improve the lives of children with chronic renal failure anemia.
- Controlled clinical trials are essential to establish definitive safety, efficacy, and optimal dosing for pediatric use.
- rHuEPO may also benefit other pediatric anemias, such as anemia of prematurity.
Abstract:
Extensive clinical studies have documented the effectiveness of recombinant human erythropoietin (rHuEPO) in correcting the anemia of adult dialysis patients, but the safety and efficacy of rHuEPO in children with renal anemia cannot yet be confirmed, due to the relative deficiency of reported studies involving pediatric subjects. To date, published experience with rHuEPO therapy in children has totaled 257 patients, although the majority of these reports have appeared only as abstracts. Overall experience has been favorable, with renal anemia and transfusion dependency successfully resolved in almost all pediatric patients reported. However, controlled clinical trials have not been performed, so it is not yet possible to clearly define the risks associated with rHuEPO therapy in children. Hypertension appears to occur or become worse in up to one third of treated children, but it is unclear to what extent rHuEPO therapy is accompanied by an increased risk of seizures, thrombosis of vascular access, hyperkalemia, hyperphosphatemia, or peritonitis (when administered via the intraperitoneal route). Only preliminary and somewhat conjectural recommendations can be offered regarding pediatric rHuEPO dosing, route of administration, special precautions, and adjunctive monitoring and therapy. Fortunately, a multicenter controlled clinical trial is underway that is designed to address these issues. Because the harmful effects of renal anemia are typically more profound for children than they are for adults, the benefits of rHuEPO promise to be even greater among pediatric patients. Whether rHuEPO therapy will substantially improve growth and neurologic and psychosocial development remains to be seen, but the potential is there for rHuEPO to dramatically improve the lives of children who suffer from the effects of the anemia of chronic renal failure. Other non-renal anemias that afflict pediatric patients, such as the anemia of prematurity, also may be amenable to rHuEPO therapy.